• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Blueberries Medical Appoints Former Clever Leaves Global Head of B2B as President of Latin American Operations

    2/10/21 9:04:15 AM ET
    $CLVR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLVR alert in real time by email

    TORONTO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce the appointment of José María Forero, the former Global Head of B2B of Clever Leaves Holdings Inc. (NASDAQ: CLVR) (“Clever Leaves”) as President of Latin American Operations, effective February 16, 2021.

    Mr. Forero is a C-level executive with 17+ years of regional and global experience in sales having led successful development of commercial departments within numerous companies, including most recently Clever Leaves, the largest medical cannabis licensed producer in Colombia. Mr. Forero is an Industrial Engineer and has an Executive MBA degree from INALDE Busines School.

    Mr. Forero has extensive knowledge of and relationships within the global cannabis industry and will utilize his operational and sales expertise to guide the next phase of the company’s international development and growth, working together with Facundo Garreton, Chairman and Interim CEO of Blueberries.

    Mr. Garreton commented: “We are pleased to welcome Mr. Forero to our team. We are confident that with the addition of Mr. Forero, our Latin American operations are well equipped for global growth and success.”

    "Blueberries has made impressive progress in a relatively short period of time developing their cultivation and extraction infrastructure," stated Mr. Forero. "With Blueberries’ state of the art extraction facility and commercial cultivation capacity established, it is well positioned to ramp up production and meet local and international demand. I am looking forward to guiding Blueberries local team in this process as well as establishing a solid operation capable of adapting to the global market conditions."

    About Blueberries Medical Corp.

    Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia and operations currently being established in Argentina. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.

    Additional information about the Company is available at www.blueberriesmed.com. For more information, please contact:

    Facundo Garretón, Chairman and Interim Chief Executive Officer
    E: [email protected]

    Ian Atacan, Chief Financial Officer
    E: [email protected]
    Tel: +1 (416) 562 3220

    Cautionary Note Regarding Forward-Looking Information
    This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to: commencement of commercial production of CBD-dominant oils and products, successful implementation of full GMP standards at its extraction facility to allow for additional export potential to international markets, achieving additional milestones is contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company’s cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes.

    These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

    Additional information regarding the Company, and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's Listing Statement dated January 31, 2019 filed on its issuer profile on SEDAR at www.sedar.com.

    No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.


    Get the next $CLVR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLVR

    DatePrice TargetRatingAnalyst
    12/23/2021$12.00 → $10.00Buy
    Canaccord Genuity
    11/12/2021$13.00 → $12.00Buy
    Canaccord Genuity
    7/27/2021$13.00Buy
    Canaccord Genuity
    7/23/2021Market Perform
    Cowen
    More analyst ratings

    $CLVR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clever Leaves Announces Voluntary Delisting and SEC Deregistration

      TOCANCIPÁ, Colombia, April 26, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, today announced that its Board of Directors (the "Board") determined to voluntarily delist its common shares, without par value (the "common shares") and warrants, each exercisable for 1/30th common share at an exercise price of $11.50 (the "Warrants" and together with the common shares, the "Securities") from The Nasdaq Stock Market LLC ("Nasdaq") and deregister its Securities in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"

      4/26/24 4:10:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Reports Fourth Quarter and Full Year 2023 Results

      - 2023 Revenue Increased 6% Year-Over-Year, with a 39% Increase in Full-Year Cannabinoid Revenue - - Drove Year-over-Year General and Administrative Expense Reductions of 26% in Q4 2023 and 24% for the Full Year - - Completed Sale of Non-Cannabinoid Herbal Brands Business on March 21, 2024 for $8.02 Million, Including $7.02 Million in Cash Paid at Closing - TOCANCIPÁ, Colombia, April 01, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2023. All financial information is provided in US doll

      4/1/24 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves and Paradise Seeds to Develop and Register Genetic Assets in Colombia

      TOCANCIPÁ, Colombia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, announced today that through its partnership with award-winning Dutch seed bank, Paradise Seeds ("Paradise"), to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third parties for cultivation across Colombia and Latin America. The two companies have already begun rigorous selection, phenotyping, and agronomic trials of several Paradise varieties at Clever Leaves'

      2/13/24 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Clever Leaves Holdings Inc.

      15-12G - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/16/24 4:45:21 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Clever Leaves Holdings Inc.

      EFFECT - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/9/24 12:15:20 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Clever Leaves Holdings Inc.

      S-8 POS - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/6/24 4:15:58 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Clever Leaves Holdings Inc. (Amendment)

      SC 13D/A - Clever Leaves Holdings Inc. (0001819615) (Subject)

      5/21/24 8:03:23 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Clever Leaves Holdings Inc.

      SC 13D - Clever Leaves Holdings Inc. (0001819615) (Subject)

      5/15/24 9:11:49 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Clever Leaves Holdings Inc. (Amendment)

      SC 13G/A - Clever Leaves Holdings Inc. (0001819615) (Subject)

      1/23/24 9:07:27 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Leadership Updates

    Live Leadership Updates

    See more
    • Clever Leaves Reminds Shareholders of its Upcoming Annual Meeting on June 2, 2023

      TOCANCIPÁ, Colombia, May 26, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, reminds shareholders that it will hold its 2023 Annual Meeting of Shareholders (the "Annual Meeting") on Friday, June 2, 2023 at 10:00 a.m. Eastern Time. The Annual Meeting will be in a virtual-only format. Clever Leaves reminds investors that its board has recommended that shareholders vote "FOR" the proposal to elect each of the five (5) nominees named in the proxy statement to the Board of Directors, "FOR" the appointment of Marcum LLP as the Company's independent registered public accounting firm to serve as in

      5/26/23 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Appoints William Muecke to Board of Directors

      BOCA RATON, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced that it has appointed William Muecke to its board of directors, effective March 25, 2022, to fill the vacancy resulting from the previously announced departure of Kyle Detwiler, the Company's current chairman and CEO, effective March 24, 2022. Muecke was also appointed to the board's nominating and governance committee, as well as its compensation committee. Muecke is a co-founder and managing member of Artemis Growth Partners, an impact-focused ESG

      3/17/22 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Announces Leadership Transition Plan

      BOCA RATON, Fla., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, today announced a leadership transition plan. Andres Fajardo, currently a director and president of the Company, has been selected to succeed Kyle Detwiler as CEO, effective March 24, 2022. Detwiler will remain CEO until March 24, 2022, to ensure a smooth transition, and he will continue to serve as the Company's Chairman until such date. "Today's leadership changes are the culmination of a succession planning process that our board and Kyle have worked on tog

      2/9/22 7:59:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity reiterated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity reiterated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      12/23/21 7:40:56 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity reiterated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $12.00 from $13.00 previously

      11/12/21 8:49:58 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity initiated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $13.00

      7/27/21 7:11:17 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Bcm Investimentos Fundo De Investimento Multimercado Credito Privado Investimento No Exterior claimed ownership of 322,234 shares (SEC Form 3)

      3 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      5/21/24 8:07:09 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hague Henry R Iii sold $563 worth of shares (170 units at $3.31), decreasing direct ownership by 1% to 11,951 units (SEC Form 4)

      4 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      3/12/24 4:50:10 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hague Henry R Iii sold $1,623 worth of shares (411 units at $3.95), decreasing direct ownership by 3% to 12,121 units (SEC Form 4)

      4 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      2/29/24 4:01:46 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Financials

    Live finance-specific insights

    See more
    • Clever Leaves Reports Third Quarter 2023 Results

      - Q3 Revenue Increased 33% Year-Over-Year, Propelled by 135% Year-Over-Year Growth in Cannabinoid Revenue, Along with 6% Year-Over-Year Growth in Non-Cannabinoid Revenue - - Q3 Adjusted EBITDA Improved Year-Over-Year to $(2.6) Million Compared to $(3.7) Million, Reflecting Revenue Growth and Continued Aggressive Expense Reductions - - Cash Balance at October 31, 2023 was $6.2 Million, with $1.9 Million in Subsequent Capital Received from the November Sale of the Company's Remaining Stake in Cansativa - - Updated Full Year 2023 Guidance Reflects Revenue Timing Shifts, Revenue Mix, and Adjusted EBITDA Improvement from Continued Operating Efficiencies - TOCANCIPÁ, C

      11/9/23 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves to Hold Third Quarter 2023 Conference Call on Thursday, November 9, 2023 at 5:00 p.m. ET

      TOCANCIPÁ, Colombia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, will hold a conference call on Thursday, November 9, 2023 at 5:00 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2023. The Company will provide its financial results in a press release prior to the conference call. Clever Leaves management will host the conference call, followed by a question-and-answer session. Conference Call Date: Thursday, November 9, 2023Time: 5:00 p.m. Eastern timeToll-free dial-in number: 1-855-238-2333International dial-in number: 1-412-317-5222Confere

      11/2/23 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Reports Second Quarter 2023 Results

      - Total Revenue Increased 21% Year-Over-Year, Driven by 151% Year-Over-Year Growth in Cannabinoid Revenue - - Continued Expense Reductions Drive Improved Adjusted EBITDA Performance of ($2.1) Million - - July 2023 Sale of Portuguese Processing Assets Added $2.7 Million in Cash Following the End of Q2 - - Reaffirming Previously Announced 2023 Guidance - TOCANCIPÁ, Colombia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, is reporting financial and operating results for the second quarter ended June 30, 2023. All financial information is provided in US dollars unless otherwise in

      8/14/23 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care